1 piramate, and 1 study each of sertraline and zonisamide.

2     As with valproic acid and carbamazepine, zonisamide (12.5 and 25 mg/kg) increased DA release in t

3       In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight

4                                              Zonisamide and pregabalin have recently obtained licence

5 lsant mood-stabilizers, valproic acid (VPA), zonisamide, and carbamazepine, but not the typical APD h

6 ormed for all medications except sertraline, zonisamide, and fluoxetine, which are summarized narrati

7 loxetine, clonazepam, ramelteon, gabapentin, zonisamide, and yokukansan.

8 f the present study was to determine whether zonisamide, another anticonvulsant mood stabilizer, as w

9 ers (AMS), valproic acid, carbamazepine, and zonisamide, but not lithium, also preferentially increas

10 etam, tiagabine, topiramate, vigabatrin, and zonisamide do not induce the metabolism of other AEDs.

11                                          The zonisamide group (n = 19) had a mean weight loss of 9.2

12                 Seventeen (57%) of 30 in the zonisamide group and 3 (10%) of 30 in the placebo group

13 th the last observation carried forward, the zonisamide group lost more body weight than the placebo

14                                              Zonisamide is a marketed antiepileptic drug that has ser

15   Patients were randomly assigned to receive zonisamide (n = 30) or placebo (n = 30).

16                                              Zonisamide therapy was started at 100 mg/d orally, with

17 t loss was an adverse effect associated with zonisamide treatment in epilepsy clinical trials.

18 s index, and percent body fat estimated that zonisamide treatment over the 16-week study duration was

19                                              Zonisamide was tolerated well, with few adverse effects.